Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa
— 24-month analysis indicated AGTC-501 was generally safe and well-tolerated, with no clinically significant safety events associated with treatment — Data demonstrates the durable profile of AGTC-501, with the higher dose cohort showing a 57% response rate in the 24-month analysis of retinal sensitivity, the primary endpoint for the trial — Benefit-risk profile supports on-going […]